Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep;94(9):1188-93.
doi: 10.3324/haematol.2009.010421.

Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations

Florence Roufosse
Review

Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations

Florence Roufosse. Haematologica. 2009 Sep.

Abstract

Hypereosinophilic syndromes are a group of disorders characterized by persistent and marked hypereosinophilia not due to an underlying disease known to cause eosinophil expansion, and which is directly implicated in damage or dysfunction of at least one target organ or tissue. In this perspective article, Dr. Roufosse provides an updated classification of these disorders and discusses the recent advances in this field, including fascinating pathogenic mechanisms and novel targeted therapeutic approaches. See related paper on page 1236.

PubMed Disclaimer

References

    1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1–27. - PubMed
    1. Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006;117:1292–302. - PubMed
    1. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–14. - PubMed
    1. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577–8. - PubMed
    1. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA. 2003;100:7830–5. - PMC - PubMed

MeSH terms